Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amazon Hurricane Heading Towards Indian Pharma?

Executive Summary

Think Amazon, think disruption, and that’s exactly what could be in store if the online retail juggernaut goes through with its rumored plans to invest in MedPlus, India’s second largest retail pharmacy chain. A deal could also have ramifications for private equity/venture capital activity in the Indian pharmacy space, say some experts.

You may also be interested in...



India Pharma In 2019: Buy, Build And Beware (Patient Power And Amazon)

2019 promises to be action-packed for Indian firms as they stay hungry for M&A and on course to transition to a more innovation-led play. But election year surprises in India, rising patient awareness, and the entry of non-traditional players like Amazon could well up the variable quotient for pharma, industry pundits tell Scrip.

Bumpy Ride Awaits Indian Firms In 2018 (And Then There’s Amazon)

2018 may not be smooth sailing for Indian firms, going by the predictions of top industry pundits. Possible upheavals on the domestic market, dynamics that demand a hawk eye on expenses and gains but also pressures as a result of FDA reforms suggest that a relatively tough year may be in store.

Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris

Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC123446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel